http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html <p class="bwalignc"> <i>Collaboration supports Charles River’s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftunelab.lilly.com%2F&amp;esheet=54555805&amp;newsitemid=20260618961171&amp;lan=en-US&amp;anchor=Lilly+TuneLab&amp;index=1&amp;md5=a097d2fb8476cb33f017a2be87671bff" shape="rect">Lilly TuneLab</a>, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). </p><p> TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more http://www.streetinsider.com/Press+Releases/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html Thu, 18 Jun 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/Press+Releases/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html <p class="bwalignc"> <i>Collaboration supports Charles River’s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftunelab.lilly.com%2F&amp;esheet=54555805&amp;newsitemid=20260618961171&amp;lan=en-US&amp;anchor=Lilly+TuneLab&amp;index=1&amp;md5=a097d2fb8476cb33f017a2be87671bff" shape="rect">Lilly TuneLab</a>, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). </p><p> TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more http://www.streetinsider.com/Press+Releases/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html Thu, 18 Jun 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/Business+Wire/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html <p class="bwalignc"> <i>Collaboration supports Charles River’s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftunelab.lilly.com%2F&amp;esheet=54555805&amp;newsitemid=20260618961171&amp;lan=en-US&amp;anchor=Lilly+TuneLab&amp;index=1&amp;md5=a097d2fb8476cb33f017a2be87671bff" shape="rect">Lilly TuneLab</a>, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). </p><p> TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more http://www.streetinsider.com/Business+Wire/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html Thu, 18 Jun 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/Business+Wire/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html <p class="bwalignc"> <i>Collaboration supports Charles River’s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftunelab.lilly.com%2F&amp;esheet=54555805&amp;newsitemid=20260618961171&amp;lan=en-US&amp;anchor=Lilly+TuneLab&amp;index=1&amp;md5=a097d2fb8476cb33f017a2be87671bff" shape="rect">Lilly TuneLab</a>, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). </p><p> TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more http://www.streetinsider.com/Business+Wire/Charles+River+Joins+Lilly+TuneLab+to+Optimize+AIML+Platform+through+Nonclinical+Testing+Expertise/26662998.html Thu, 18 Jun 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/General+News/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html <p>Investing.com -- Morgan Stanley upgraded contract research organization (CRO) provider Charles River Laboratories while downgrading IQVIA, arguing that improving biotech funding and portfolio changes create a more attractive risk-reward profile for Charles River, while longer-term uncertainty tied to artificial intelligence and pharma insourcing weighs on IQVIA.</p><p data-start="387" data-end="835">The brokerage said demand conditions for preclinical research are showing signs of recovery as biopharma funding improves, increasing the likelihood of a turnaround in Charles River's Discovery and Safety Assessment business. Recent acquisitions and divestitures are also expected to sharpen the company's focus on core operations, including regulated safety assessment, research models, and http://www.streetinsider.com/General+News/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html Wed, 17 Jun 2026 08:47:08 -0400 CRL IQV http://www.streetinsider.com/General+News/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html <p>Investing.com -- Morgan Stanley upgraded contract research organization (CRO) provider Charles River Laboratories while downgrading IQVIA, arguing that improving biotech funding and portfolio changes create a more attractive risk-reward profile for Charles River, while longer-term uncertainty tied to artificial intelligence and pharma insourcing weighs on IQVIA.</p><p data-start="387" data-end="835">The brokerage said demand conditions for preclinical research are showing signs of recovery as biopharma funding improves, increasing the likelihood of a turnaround in Charles River's Discovery and Safety Assessment business. Recent acquisitions and divestitures are also expected to sharpen the company's focus on core operations, including regulated safety assessment, research models, and http://www.streetinsider.com/General+News/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html Wed, 17 Jun 2026 08:47:08 -0400 CRL IQV http://www.streetinsider.com/Investing/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html <p>Investing.com -- Morgan Stanley upgraded contract research organization (CRO) provider Charles River Laboratories while downgrading IQVIA, arguing that improving biotech funding and portfolio changes create a more attractive risk-reward profile for Charles River, while longer-term uncertainty tied to artificial intelligence and pharma insourcing weighs on IQVIA.</p><p data-start="387" data-end="835">The brokerage said demand conditions for preclinical research are showing signs of recovery as biopharma funding improves, increasing the likelihood of a turnaround in Charles River's Discovery and Safety Assessment business. Recent acquisitions and divestitures are also expected to sharpen the company's focus on core operations, including regulated safety assessment, research models, and http://www.streetinsider.com/Investing/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html Wed, 17 Jun 2026 08:47:08 -0400 CRL IQV http://www.streetinsider.com/Investing/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html <p>Investing.com -- Morgan Stanley upgraded contract research organization (CRO) provider Charles River Laboratories while downgrading IQVIA, arguing that improving biotech funding and portfolio changes create a more attractive risk-reward profile for Charles River, while longer-term uncertainty tied to artificial intelligence and pharma insourcing weighs on IQVIA.</p><p data-start="387" data-end="835">The brokerage said demand conditions for preclinical research are showing signs of recovery as biopharma funding improves, increasing the likelihood of a turnaround in Charles River's Discovery and Safety Assessment business. Recent acquisitions and divestitures are also expected to sharpen the company's focus on core operations, including regulated safety assessment, research models, and http://www.streetinsider.com/Investing/Morgan+Stanley+favors+Charles+River+Over+IQVIA+in+CRO+sector+reset/26657445.html Wed, 17 Jun 2026 08:47:08 -0400 CRL IQV http://www.streetinsider.com/Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Hot+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Hot+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Hot+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Hot+Comments/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Hot+Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Hot+Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Hot+Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh downgraded IQVIA Holdings (NYSE: IQV) from Overweight to Equalweight with a price target of $200.00 (from $225.00).</p><p>The analyst comments "IQV - Moving to Equal-weight w/ $200 PT: Scanning through Street numbers, we struggle to identify clear drivers of upside for IQV relative to the CRL setup. Longerterm, we're also somewhat skeptical on margin expansion from today's levels, with our survey work continuing to imply sponsor appetite to increase Functional Service Provider (FSP) mix relative to Full-Service Outsourcing (FSO), while a more tangible benefit from AI cost savings is http://www.streetinsider.com/Hot+Downgrades/Morgan+Stanley+Downgrades+IQVIA+Holdings+%28IQV%29+to+Equalweight/26656522.html Wed, 17 Jun 2026 06:30:57 -0400 CRL IQV http://www.streetinsider.com/Hot+Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) from Equalweight to Overweight with a price target of $220.00 (from $185.00).</p><p>The analyst comments "CRL - Moving to Overweight w/ $220 PT: With a strong uptick in biopharma funding beginning to transition into RFPs and bookings, we think CRL is well positioned to benefit given its leading preclinical capabilities. We also believe recent acquisitions and divestitures offer clear upside risk to Street numbers from 2027onward and help to reduce areas of historical volatility through the P&L (e.g. building out a more reliable http://www.streetinsider.com/Hot+Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html Wed, 17 Jun 2026 06:30:24 -0400 CRL IQV http://www.streetinsider.com/Hot+Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) from Equalweight to Overweight with a price target of $220.00 (from $185.00).</p><p>The analyst comments "CRL - Moving to Overweight w/ $220 PT: With a strong uptick in biopharma funding beginning to transition into RFPs and bookings, we think CRL is well positioned to benefit given its leading preclinical capabilities. We also believe recent acquisitions and divestitures offer clear upside risk to Street numbers from 2027onward and help to reduce areas of historical volatility through the P&L (e.g. building out a more reliable http://www.streetinsider.com/Hot+Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html Wed, 17 Jun 2026 06:30:24 -0400 CRL IQV http://www.streetinsider.com/Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) from Equalweight to Overweight with a price target of $220.00 (from $185.00).</p><p>The analyst comments "CRL - Moving to Overweight w/ $220 PT: With a strong uptick in biopharma funding beginning to transition into RFPs and bookings, we think CRL is well positioned to benefit given its leading preclinical capabilities. We also believe recent acquisitions and divestitures offer clear upside risk to Street numbers from 2027onward and help to reduce areas of historical volatility through the P&L (e.g. building out a more reliable http://www.streetinsider.com/Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html Wed, 17 Jun 2026 06:30:24 -0400 CRL IQV http://www.streetinsider.com/Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) from Equalweight to Overweight with a price target of $220.00 (from $185.00).</p><p>The analyst comments "CRL - Moving to Overweight w/ $220 PT: With a strong uptick in biopharma funding beginning to transition into RFPs and bookings, we think CRL is well positioned to benefit given its leading preclinical capabilities. We also believe recent acquisitions and divestitures offer clear upside risk to Street numbers from 2027onward and help to reduce areas of historical volatility through the P&L (e.g. building out a more reliable http://www.streetinsider.com/Upgrades/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html Wed, 17 Jun 2026 06:30:24 -0400 CRL IQV http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) from Equalweight to Overweight with a price target of $220.00 (from $185.00).</p><p>The analyst comments "CRL - Moving to Overweight w/ $220 PT: With a strong uptick in biopharma funding beginning to transition into RFPs and bookings, we think CRL is well positioned to benefit given its leading preclinical capabilities. We also believe recent acquisitions and divestitures offer clear upside risk to Street numbers from 2027onward and help to reduce areas of historical volatility through the P&L (e.g. building out a more reliable http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html Wed, 17 Jun 2026 06:30:24 -0400 CRL IQV http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) from Equalweight to Overweight with a price target of $220.00 (from $185.00).</p><p>The analyst comments "CRL - Moving to Overweight w/ $220 PT: With a strong uptick in biopharma funding beginning to transition into RFPs and bookings, we think CRL is well positioned to benefit given its leading preclinical capabilities. We also believe recent acquisitions and divestitures offer clear upside risk to Street numbers from 2027onward and help to reduce areas of historical volatility through the P&L (e.g. building out a more reliable http://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html Wed, 17 Jun 2026 06:30:24 -0400 CRL IQV http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html (Updated - June 17, 2026 6:30 AM EDT) <p>Morgan Stanley analyst Kallum Titchmarsh upgraded Charles River Labs (NYSE: CRL) from Equalweight to Overweight with a price target of $220.00 (from $185.00).</p><p>The analyst comments "CRL - Moving to Overweight w/ $220 PT: With a strong uptick in biopharma funding beginning to transition into RFPs and bookings, we think CRL is well positioned to benefit given its leading preclinical capabilities. We also believe recent acquisitions and divestitures offer clear upside risk to Street numbers from 2027onward and help to reduce areas of historical volatility through the P&L (e.g. building out a more reliable http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Upgrades+Charles+River+Labs+%28CRL%29+to+Overweight%2C+%27strong+uptick+in+biopharma+funding+beginning+to+transition+into+RFPs+and+bookings%27/26656521.html Wed, 17 Jun 2026 06:30:24 -0400 CRL IQV